宏基因组二代测序对ICU重症社区获得性肺炎临床结局的影响:多中心随机对照试验
该多中心随机对照开放标签试验在10个ICU纳入349例重症社区获得性肺炎患者,比较支气管肺泡灌洗液仅行常规微生物检测与联合宏基因组二代测序的临床改善时间。结果显示联合mNGS组临床改善时间优于常规检测组(10天 vs 13天),14天内临床改善比例更高(62.0% vs 46.5%),其他次要结局无显著差异。
要点
- 在ICU重症社区获得性肺炎患者中,BALF联合mNGS较仅用常规微生物检测缩短临床改善时间。
- 联合mNGS组14天内临床改善比例为62.0%,高于常规检测组的46.5%。
- 其他次要结局两组间无显著差异。
核心结论
- 与单独使用常规微生物检测相比,mNGS联合常规微生物检测可缩短重症社区获得性肺炎患者的临床改善时间。
主要发现
- 意向性分析中,mNGS组临床改善时间优于常规检测组(10天 vs 13天;差值-2.0天;95%CI -3.0至0.0天)。
- 符合方案分析获得相似结果。
- 14天内临床改善比例mNGS组为62.0%,常规检测组为46.5%,差异显著。
- 其他次要结局无显著差异。
关键数值与推荐
- 主要结局为临床改善时间,定义为从随机化至六分类序贯量表改善2分或转出ICU(以先发生者为准)。
- BALF评估方式:常规检测组仅行常规微生物检测,mNGS组行mNGS联合常规微生物检测。
临床怎么用
- 对ICU重症社区获得性肺炎患者,可考虑在常规微生物检测基础上联合BALF mNGS以促进临床改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metagenomic next-generation sequencing (mNGS) was previously established as a method that can increase the pathogen identification rate in patients with severe community-acquired pneumonia (SCAP). RESEARCH QUESTION: What is the impact on clinical outcomes of mNGS of BAL fluid (BALF) in patients with SCAP in the ICU? STUDY DESIGN AND METHODS: A multicenter randomized controlled open-label clinical trial was conducted in 10 ICUs. Patients were randomized in a 1:1 ratio to undergo BALF assessment with conventional microbiological tests (CMTs) only (ie, the CMT group) or BALF assessment with both mNGS and CMTs (ie, the mNGS group). The primary outcome was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a six-category ordinal scale or discharge from the ICU, whichever occurred first. RESULTS: A total of 349 patients were randomized to treatment between January 1, 2021, and November 18, 2022; 170 were assigned to the CMT group and 179 to the mNGS group. In the intention-to-treat analysis, the time to clinical improvement was better in the mNGS group than in the CMT group (10 days vs 13 days; difference, -2.0 days; 95% CI, -3.0 to 0.0 days). Similar results were obtained in the per-protocol analysis. The proportion of patients with clinical improvement within 14 days was significantly higher in the mNGS group (62.0%) than in the CMT group (46.5%). There was no significant difference in other secondary outcomes. INTERPRETATION: We found that compared with the use of CMTs alone, mNGS combined with CMTs reduced the time to clinical improvement for patients with SCAP. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR; www.chictr.org.cn/index.html; ChiCTR2000037894.
引用
- Wu, Sun, He, et al. Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia in the ICU: A Multicenter, Randomized Controlled Trial. Chest. 2024. PMID: 39067508. doi:10.1016/j.chest.2024.07.144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。